BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16077935)

  • 21. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
    Nobukini T; Thomas G
    Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
    Astrinidis A; Henske EP
    Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.
    Nellist M; Burgers PC; van den Ouweland AM; Halley DJ; Luider TM
    Biochem Biophys Res Commun; 2005 Aug; 333(3):818-26. PubMed ID: 15963462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation.
    Miloloza A; Kubista M; Rosner M; Hengstschläger M
    J Neuropathol Exp Neurol; 2002 Feb; 61(2):154-63. PubMed ID: 11853018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of PCNA and CAF-1 expression by the two tuberous sclerosis gene products.
    Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
    Biochem Biophys Res Commun; 2003 Aug; 307(3):737-42. PubMed ID: 12893285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal giant cells in the cerebral lesions of tuberous sclerosis complex.
    Mizuguchi M
    Congenit Anom (Kyoto); 2007 Mar; 47(1):2-8. PubMed ID: 17300684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian patients with tuberous sclerosis complex.
    Ali M; Girimaji SC; Markandaya M; Shukla AK; Sacchidanand S; Kumar A
    Acta Neurol Scand; 2005 Jan; 111(1):54-63. PubMed ID: 15595939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of TSC2 stop codon variants found in tuberous sclerosis patients.
    Goedbloed MA; Nellist M; Verhaaf B; Reuser AJ; Lindhout D; Sunde L; Verhoef S; Halley DJ; van den Ouweland AM
    Eur J Hum Genet; 2001 Nov; 9(11):823-8. PubMed ID: 11781698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex.
    Hung CC; Su YN; Chien SC; Liou HH; Chen CC; Chen PC; Hsieh CJ; Chen CP; Lee WT; Lin WL; Lee CN
    BMC Med Genet; 2006 Sep; 7():72. PubMed ID: 16981987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
    Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
    J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex.
    Choi JE; Chae JH; Hwang YS; Kim KJ
    Brain Dev; 2006 Aug; 28(7):440-6. PubMed ID: 16554133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel TSC2 mutations and decreased expression of tuberin in cultured tumor cells with an insertion mutation.
    Feng JH; Yamamoto T; Nanba E; Ninomiya H; Oka A; Ohno K
    Hum Mutat; 2004 Apr; 23(4):397. PubMed ID: 15024740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A role of the tuberous sclerosis gene-2 product during neuronal differentiation.
    Soucek T; Hölzl G; Bernaschek G; Hengstschläger M
    Oncogene; 1998 Apr; 16(17):2197-204. PubMed ID: 9619828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and prognostic value of tuberous sclerosis complex 2 gene product tuberin in human pancreatic cancer.
    Kataoka K; Fujimoto K; Ito D; Koizumi M; Toyoda E; Mori T; Kami K; Doi R
    Surgery; 2005 Sep; 138(3):450-5. PubMed ID: 16213898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hamartin and tuberin expression in human tissues.
    Johnson MW; Kerfoot C; Bushnell T; Li M; Vinters HV
    Mod Pathol; 2001 Mar; 14(3):202-10. PubMed ID: 11266527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations.
    Jansen FE; Braams O; Vincken KL; Algra A; Anbeek P; Jennekens-Schinkel A; Halley D; Zonnenberg BA; van den Ouweland A; van Huffelen AC; van Nieuwenhuizen O; Nellist M
    Neurology; 2008 Mar; 70(12):908-15. PubMed ID: 18032745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of all exons of TSC1 and TSC2 genes for germline mutations in Japanese patients with tuberous sclerosis: report of 10 mutations.
    Yamashita Y; Ono J; Okada S; Wataya-Kaneda M; Yoshikawa K; Nishizawa M; Hirayama Y; Kobayashi E; Seyama K; Hino O
    Am J Med Genet; 2000 Jan; 90(2):123-6. PubMed ID: 10607950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles.
    Plank TL; Yeung RS; Henske EP
    Cancer Res; 1998 Nov; 58(21):4766-70. PubMed ID: 9809973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder.
    Knowles MA; Habuchi T; Kennedy W; Cuthbert-Heavens D
    Cancer Res; 2003 Nov; 63(22):7652-6. PubMed ID: 14633685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues.
    Wienecke R; Maize JC; Reed JA; de Gunzburg J; Yeung RS; DeClue JE
    Am J Pathol; 1997 Jan; 150(1):43-50. PubMed ID: 9006320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.